Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer

WALTHAM, Mass., Oct. 1, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of inflammatory bowel disease ("IBD"), today announced the appointment of Sheldon Sloan, M.D., M. Bioethics, as Chief Medical Officer. Dr. Sloan brings more than 25 years of experience in both large pharmaceutical and small biotech companies with an extensive track record of program leadership in the field of Inflammation and Immunology. This includes more than 15 years in various leadership roles at J&J, followed by Vice President and program lead for estrasimod in ulcerative colitis at Arena Pharmaceuticals ("Arena") and Pfizer, and most recently CMO and program lead for obefazimod in ulcerative colitis at Abivax S.A. ("Abivax").

"Sheldon's distinguished career provides numerous examples of the talent, leadership, and determination required to create and deliver innovative new therapies to patients in need," said Cameron Turtle, DPhil, chief executive officer of Spyre. "We have an ambitious roadmap ahead of us as we continue our effort to advance each of our programs into the clinic over the next several months and initiate Phase 2 studies in 2025. We are grateful to have Sheldon on board to scale and lead our medical organization to deliver on these goals."

Dr. Sloan is the former Chief Medical Officer at Abivax where he led the Phase 3 development of obefazimod, responsible for medical strategy, lifecycle strategy, and building medical infrastructure including Clinical Development, Pharmacovigilance, Bioinformatics, Medical Affairs, and Clinical Pharmacology. Prior to Abivax, Dr. Sloan led the development of etrasimod at Arena, and Pfizer, after Arena's acquisition, where he was responsible for planning, execution, and global submission of the ulcerative colitis program. Prior to joining Arena, Dr. Sloan held leadership positions at J&J in Medical Affairs, R&D, and Science Policy. In his last position at J&J, he was Global Medical Affairs Lead for IBD, responsible for the global launch in Crohn's disease and ulcerative colitis for Stelara. Dr. Sloan holds an M.D. from Rush Medical College, and a Master of Bioethics from the University of Pennsylvania. Dr. Sloan currently serves on the Columbia University Masters of Bioethics Advisory Board, the Drexel University Dornsife School of Public Health Dean's Impact, Advancement and Learning Council, and the American Gastroenterological Association Ethics Committee.

"Spyre is pursuing what I believe to be an unrivaled strategy in the field by engineering potentially best-in-class antibodies against the top targets within IBD and advancing them as combination product candidates with the potential to be delivered on an infrequent basis," said Dr. Sloan. "I'm excited to join the team and continue to build its medical organization to advance Spyre's programs into Phase 2 studies in 2025."

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation of inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.

For more information, please visit http://spyre.com. 

Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical fact are forward-looking statements. These forward-looking statements include statements regarding the Company's business strategy, including the Company's potential success of developing therapeutics for IBD, the potential contributions of Dr. Sloan, including the development of the Company's medical organization to advance its programs into Phase 2 studies in 2025, the potential efficacy and safety profile of its product candidates, the potential therapeutic benefits of its product candidates and the timing of clinical trials, including the commencement of Phase 2 studies. The words "believe," "may," "will," "potentially," "estimate," "continue," "anticipate," "predict," "target," "intend," "could," "would," "should," "project," "plan," "expect," the negatives of these terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Spyre's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited those uncertainties and factors described under the heading "Risk Factors" and "Note about Forward-Looking Statements" in Spyre's most recent Quarterly Report on Form 10-Q filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors included in other filings by Spyre from time to time. Should one or more of these risks or uncertainties materialize, or should any of Spyre's assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth therein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Spyre does not undertake or accept any duty to make any updates or revisions to any forward-looking statements. This press release does not purport to summarize all of the conditions, risks and other attributes of an investment in Spyre.

SOURCE Spyre Therapeutics, Inc.